How Does Liminal BioSciences Inc (LMNL) Stock Rank on Wall Street Thursday?

Thursday, June 30, 2022 12:47 PM | InvestorsObserver Analysts

Mentioned in this article

How Does Liminal BioSciences Inc (LMNL) Stock Rank on Wall Street Thursday?

InvestorsObserver is giving Liminal BioSciences Inc (LMNL) an Analyst Rating Rank of 5, meaning LMNL is ranked higher by analysts than 5% of stocks. The average price target for LMNL is $2 and analyst’s rate the stock as a Hold.

Wall Street analysts are rating LMNL a Hold today. Find out what this means to you and get the rest of the rankings on LMNL!

See Full LMNL Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Liminal BioSciences Inc Stock Today?

Liminal BioSciences Inc (LMNL) stock is higher by 20% while the S&P 500 has fallen -0.31% as of 12:47 PM on Thursday, Jun 30. LMNL has risen $0.09 from the previous closing price of $0.45 on volume of 249,091 shares. Over the past year the S&P 500 is down -11.42% while LMNL has fallen -86.12%. LMNL earned $0.61 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 0.89. Click Here to get the full Stock Report for Liminal BioSciences Inc stock.